(Chloro-4 phenyl) thiomethylene biphosphonate in Paget's bone disease.
Several biphosphonates (PCT) have been used as therapeutic agents for Paget's bone disease. CIPsMBP has recently been shown to have a significant antiosteoclastic activity while defect in mineralization was only apparent at high doses. For six months, we tested this drug in 23 pagetic patients distributed in three groups. Gr 1 (n = 5) receiving 200 mg/day showed a decrease of serum alkaline phosphatase (SAP) to 42 +/- 4% (p less than 0.01) of initial value (100%) while hydroxyprolinuria/creatinuria ratio (OH/Cr) dropped to 69 +/- 8% of baseline. In 4 patients receiving 400 mg/day, SAP improved to 48 +/- 9% of initial value (p less than 0.01) and OH/Cr to 40 +/- 3% (p less than 0.01). In the last group (n = 14) receiving 200 mg/day for 3 months, and 400 mg/day thereafter up to the 6th month SAP reduced to 53 +/- 4% and OH/Cr to 62 +/- 6% of initial value (p less than 0.01). Clinical improvement was significant from the first month of treatment. No resistance (mean decrease of SAP lower than 30%) was recorded and no radiological or clinical evidence of mineralization defect appeared. The clinical and biological tolerance was excellent throughout the study.
Reginster
J Y
JY
Deroisy
R
R
Lecart
M P
MP
Franchimont
P
P
D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood; D001862:Bone Resorption / Q000517:prevention & control; D004164:Diphosphonates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy*
D004164:Diphosphonates; C058651:tiludronic acid; D000469:Alkaline Phosphatase